Immuneering Corporation
NASDAQ:IMRX
1.93 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0.317 | 2.08 | 2.312 | 1.92 |
| Cost of Revenue
| 0.764 | 0.158 | 1.153 | 1.28 | 1.223 |
| Gross Profit
| -0.764 | 0.159 | 0.927 | 1.031 | 0.697 |
| Gross Profit Ratio
| 0 | 0.501 | 0.446 | 0.446 | 0.363 |
| Reseach & Development Expenses
| 41.624 | 36.267 | 26.541 | 15.004 | 4.279 |
| General & Administrative Expenses
| 16.76 | 15.607 | 8.272 | 3.11 | 2.709 |
| Selling & Marketing Expenses
| -16,743.354 | 0 | 0 | 0 | 0 |
| SG&A
| 16.76 | 15.607 | 8.272 | 3.11 | 2.709 |
| Other Expenses
| 0.029 | 0.03 | -0.127 | 0 | 0 |
| Operating Expenses
| 58.413 | 51.904 | 34.813 | 18.114 | 6.988 |
| Operating Income
| -58.413 | -51.745 | -33.886 | -17.083 | -6.291 |
| Operating Income Ratio
| 0 | -163.258 | -16.292 | -7.39 | -3.277 |
| Total Other Income Expenses Net
| 4.941 | 1.231 | 0.043 | 0.043 | -1.418 |
| Income Before Tax
| -53.472 | -50.514 | -33.843 | -17.04 | -7.709 |
| Income Before Tax Ratio
| 0 | -159.373 | -16.271 | -7.372 | -4.016 |
| Income Tax Expense
| 0 | -1.232 | -0.307 | -0.084 | 0.351 |
| Net Income
| -53.472 | -49.282 | -33.536 | -17.04 | -8.061 |
| Net Income Ratio
| 0 | -155.487 | -16.123 | -7.372 | -4.199 |
| EPS
| -1.88 | -1.87 | -1.27 | -0.67 | -0.32 |
| EPS Diluted
| -1.88 | -1.87 | -1.27 | -0.67 | -0.32 |
| EBITDA
| -58.061 | -51.715 | -33.886 | -16.961 | -7.34 |
| EBITDA Ratio
| 0 | -163.163 | -16.292 | -7.337 | -3.824 |